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Abstract
The Centers for Disease Control and Prevention have listed the potential bioweapon ricin as a Category B Agent. Ricin is a
so-called A/B toxin produced by plants and is one of the deadliest molecules known. It is easy to prepare and no curative
treatment is available. An immunotherapeutic approach could be of interest to attenuate or neutralise the effects of the
toxin. We sought to characterise neutralising monoclonal antibodies against ricin and to develop an effective therapy. For
this purpose, mouse monoclonal antibodies (mAbs) were produced against the two chains of ricin toxin (RTA and RTB).
Seven mAbs were selected for their capacity to neutralise the cytotoxic effects of ricin in vitro. Three of these, two anti-RTB
(RB34 and RB37) and one anti-RTA (RA36), when used in combination improved neutralising capacity in vitro with an IC50 of
31 ng/ml. Passive administration of association of these three mixed mAbs (4.7 mg) protected mice from intranasal
challenges with ricin (5 LD50). Among those three antibodies, anti-RTB antibodies protected mice more efficiently than the
anti-RTA antibody. The combination of the three antibodies protected mice up to 7.5 hours after ricin challenge. The strong
in vivo neutralising capacity of this three mAbs combination makes it potentially useful for immunotherapeutic purposes in
the case of ricin poisoning or possibly for prevention.
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Introduction
Ricin is a 60–64 kDa glycoprotein of the A–B toxin family,
found in the castor bean plant Ricinus communis [25]. The toxin
consists of two subunits (A and B) linked by a disulfide bridge. The
B-chain (RTB) is a galactose-specific lectin which folds into two
globular domains, each binding a galactose or N-acetyl galactos-
amine residue present on glycoproteins and glycolipids at the cell
surface [29]. This binding allows ricin to be internalised by
endocytosis and retrograde transported to the endoplasmic
reticulum where the interchain disulfide bonds are reduced [30].
The A-chain (RTA) is translocated to the cytosol, where its strong
N-glycosidase activity depurinates an adenine residue of the 28 S
ribosomal RNA loop contained within the 60 S subunit [10]. This
irreversible process inactivates elongation of polypeptides and
leads to cell death.
Because of its high lethality, relative ease of dissemination and
availability, the Centers for Disease Control and Prevention
consider ricin as a Category B Agent. The symptoms and severity
of ricin poisoning depend on the delivery route, the parenteral one
being the most toxic [31]. As a bioweapon for terrorism,
aerosolised ricin is considered a serious threat and leads to severe
lung damage and possibly death. In humans, the estimated lethal
dose of ricin is 1–25 mg/kg, administered by injection or
inhalation [1,12]. Currently, no antidote is available for ricin
poisoning or prevention [4]. Although several types of therapy are
under development, present treatment of possible victims could
only be palliative. The literature describes previous attempts to
produce vaccines [26,32,36], inhibitors of the RTA catalytic
activity like chemicals [37], aptamers containing non-natural sugar
and purine derivatives [34] and even sugar analogues that prevent
binding of ricin to its target [2]. New chemical compounds have
been recently described, which inhibit retrograde transport of ricin
in the cell, preventing this one to reach its ribosome target [33].
Passive immunisation still remains one of the most effective
therapies, immediately active and very specific, allowing the use of
low doses of antibodies [3]. In order to prevent ricin poisoning,
neutralising antibodies are needed for pre-exposure prophylaxis as
well as curative treatment.
In the present study, we produced several murine monoclonal
antibodies (mAbs) directed against RTA or RTB and tested them
for their neutralising activity against ricin toxin in vitro. Seven were
active and a combination of three proved most effective: RB34
and RB37 (two anti-RTB mAbs) with RA36 (an anti-RTA mAb).
In an in vivo mouse protection assay with intranasal challenges of
ricin, this combination of three antibodies afforded powerful
protection at low concentration. These neutralising mAbs are of
great interest for passive immunotherapy for the treatment of ricin
poisoning or for pre-exposure prophylaxis.
Results
Production of specific mAbs against RTA and RTB
To produce neutralising mAbs against ricin and bypass the
natural strong toxicity of this toxin, Balb/c mice were immunised
with either the A or the B chain of ricin. However, initial
immunisation using 12.5 mg of RTA led to death of the mice,
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Screening of hybridoma supernatants by EIA allowed us to verify
the specificity of the antibodies via their binding to A or B chain
conjugates. Among a total of 1063 hybridomas from six fusions of
spleen cells of mice immunised with RTA, 44 were found to
secrete anti-RTA antibodies, and the best 11 clones were selected.
A total of 525 hybridomas resulted from the RTB fusion, and 49
clones were found to be positive during screening. Among these,
20 hybridomas were finally selected and stabilised for further
investigation. All these different mAbs also recognised the whole
toxin, in addition to the separate chain used for their production.
Monoclonal antibody properties
Antibody binding compatibility. A two-site immunometric
assay using purified ricin was set up to establish mAb pairs able to
bind to the whole toxin simultaneously in vitro. All possible
combinations of mAb pairs, one for capture and the other biotin-
labeled as conjugate, were evaluated (data not shown). A single
concentration of ricin was tested (100 ng/ml) in triplicate and
compared with nonspecific binding. Selected results obtained with
the best mAb conjugates are summarised in Table 1. This allowed
us to characterise the mAbs recognising the same (or at least an
overlapping) epitope and to define rough specificity groups.
Among the antibodies directed against RTB, two (RB34 and
RB27) belonged to the same group, while all others (RB13, RB14,
RB15, RB24, RB37, RB42 and RB43) were compatible with each
other and with these two antibodies. Among the antibodies
directed against RTA, RA36 was not compatible with RA30 and
RA35, but these two were fully compatible. On the other hand,
RA32 and RA33 recognised the same epitopic region and were
not compatible. The best results were obtained using mAbs RB14
and RB42 as capture antibodies combined with biotin-labeled
RB34, RA35 and RA36 (data not shown).
Screening of antibodies in immunoblot. The 20 anti-RTB
and 11 anti-RTA antibodies were tested for their capacity to
recognise denatured ricin in reducing conditions in SDS-PAGE/
western blotting analysis (Fig. 1). Four out of the 31 antibodies
bound the denatured protein and thus possibly a linear epitope
during immunoblot experiments (RA31 RA33, RA35 and RB37,
Fig. 1).
In vitro screening of neutralizing mAbs. All mAbs were
tested for their ability to neutralise ricin cytotoxicity in vitro. The
ricin concentration necessary to kill more than 95% of Jurkat cells
was first determined in a preliminary study (Fig. 2A). A cytotoxic
dose that killed 50% of cells (CD50) was determined to be 1 pg/ml.
A ricin concentration of 0.1 ng/ml was used for antibody
screening using 1000 cells per well. The capacity of mAbs to
neutralise ricin cytotoxicity was tested using a viability assay.
Among the 31 antibodies, seven had a neutralising effect on ricin
toxicity (viability greater than 10% at 1 mg/ml), including 4 anti-
RTA antibodies, i.e. RA32, RA33, RA35 and RA36, and 3 anti-
RTB antibodies, i.e. RB27, RB34 and RB37 (patterns shown in
Fig. 2B and 2C, respectively). Non-neutralising antibodies, RA30
and RB18 (representative of all the non-neutralising anti-RTA and
anti-RTB antibodies, respectively) are shown as negative controls
(less than 5% cell viability at 10 mg/ml). The anti-RTB
neutralising mAbs afforded total protection (i.e. 100% cell
viability) in vitro, whereas this was never achieved even with the
highest concentration of anti-RTA mAbs (10 mg/ml, Fig. 2B).
Concentrations of neutralising antibodies necessary to maintain
50% cell viability were determined (Table 2). RB34 was the most
powerful neutralising mAb, with an IC50 of only 58 ng/ml,
Table 1. Combination assay of antibody binding to ricin.
Biotin-labeled mAbs
Anti-RTB Anti-RTA
RB27 RB34 RB37 RA30 RA31 RA33 RA35 RA36
RB13 + + + + + + ++ +
RB14 ++ ++ ++ ++ ++ ++ ++ ++
RB15 + + + + + + + +
Anti-RTB RB24 + + + + + + ++ +
RB27 2 2 ++ + ++ + ++ ++
RB34 2 2 ++ + ++ + ++ ++
RB37 ++ ++ 2 ++ ++ + ++ ++
RB42 ++ ++ + ++ ++ ++ ++ ++
RB43 + + + + + + ++ +
RA28 + ++ ++ + + + ++ ++
RA30 ++ ++ ++ 2 + ++ ++ 2
Anti-RTA RA31 ++ ++ ++ ++ 2 ++ ++ +
RA32 + ++ ++ + + 2 ++ ++
RA33 + ++ ++ ++ ++ 2 ++ ++
RA35 ++ ++ ++ + + ++ 2 2
RA36 ++ ++ ++ 2 + ++ 2 2
A two-site immunometric test was carried out using one capture antibody immobilized on solid phase (1 mg/well) and the other as a biotin-labeled conjugate (100 ng/
ml) with ricin at 100 ng/ml. Absorbance was measured after 1 h reaction with Ellman reagent and reported in the table according to the signal intensity: (2) ,100 mAu;
(+) between 100 and 1200 mAu and (++) .1200 mAu.
doi:10.1371/journal.pone.0020166.t001
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the other mAbs (Table 2).
Combination of mAbs to neutralise ricin in vitro. With a
view to increasing ricin neutralisation, protective mAbs were tested
in combination. Pairs of antibodies (1:1 ratio) were evaluated using
the same protocol described for screening of the antibodies. As
shown in Figure 3A, some mAb pairs showed an additive effect as
compared with the mAbs used singly. Best neutralising effects were
obtained with pairs including RB34, in particular RB34/RB37
(Fig. 3A), which had an IC50 of 41 ng/ml (Table 2). Combination
of three and even four mAbs was also tested (Fig. 3B). A slightly
greater neutralising effect was observed by adding RA36 to the
combination RB34/RB37, with an estimated IC50 of 31 ng/ml,
which is roughly half that obtained with RB34 alone (Table 2). No
additional effect was found by including a fourth mAb (data not
shown). RB34 combined with RB37 and RA36 gave cells the
greatest protection against ricin in vitro. Based on these data, these
three antibodies were selected for further characterisation.
RB34, RB37 and RA36 characterisation
Binding kinetics. Kinetic parameters of the three antibodies
were measured by Surface Plasmon Resonance biosensor
technology using ricin as antigen (Table 3). The dissociation
constant, KD, was calculated from the ratio of koff/kon. RB34,
RB37 and RA36 exhibit approximately the same KD in the range
of 10
210 M, partly due to a very small dissociation rate ranging
from 3.66 10
25 s
21 for RB34 to 7.34 10
25 s
21 for RB37 (Table 3).
These very slow koff allow us to estimate a minimum half-life of
2 h, 2.5 h and 3.8 h for the RB37, RA36 and RB34/ricin
complexes, respectively. However, these data do not indicate what
the half-life would be for the corresponding quaternary complex of
ricin and the three-mAb combination.
Pharmacokinetic studies of RA36, RB34 and RB37 in
mice. In order to evaluate the time-window of action of the
neutralising antibodies in prophylaxis, it seemed important to
determine the half-lives of the different mAbs in mice. After
intraperitoneal injection of antibodies in mice, plasma
concentrations of RB34, RB37 and RA36 were measured by
EIA at different times post-injection. As shown in Figure 4, an
initial rapid plasma increase was observed within the first hours
after injection for the three antibodies, corresponding to the
antibody transfer from the peritoneum to the blood compartment.
A peak was reached approximately 18–24 h post-injection,
followed by a decrease during the subsequent five weeks. RA36
peaked at 15 mg/ml, whereas RB34 and RB37 were less
concentrated (10 mg/ml), a couple of hours after injection.
Values when included in a pharmacokinetic (noncompartmental)
model allowed evaluating an half-life of 13.2, 14.5 and 17.5 days
for RB34, RA36 and RB37, respectively. Then even if the peak
plasma concentration was a bit higher for RA36 than for the other
mAbs during the first day after injection, the half-lives of these
three mAbs are close.
Mouse protection assay of anti-ricin antibodies. The
ability of the RB34, RB37 and RA36 antibodies to neutralise ricin
simultaneously was studied using a mouse model for ricin
poisoning by intranasal challenge. Ricin was used at 5 LD50
(7.5 mg/kg) with several doses of antibodies and survival rate was
followed for 21 days (Fig. 5). The antibody combination afforded
mice effective protection against ricin poisoning, effectiveness
increasing proportionally with the quantity of antibodies. The
lowest dose of antibodies (antibody/ricin ratio=2) did not protect
mice, but improved their survival compared with control. With the
dose of antibodies corresponding to a ratio 5, a significant
protection of mice as compared to the non specific control
antibodies was observed (50% viability, fig. 5A). The increase of
antibodies concentration (R=10) allows to reach 100% of
protection (Fig. 5A). The analysis of mice weight provided
comparable results since the weight loss decreased as the
antibody/ricin ratio increased (from 224 to 27%, for a ratio
increase from 5 to 20). This mix of antibodies neutralised ricin
with great efficiency in vivo, and protected the mice against ricin
poisoning (5 LD50) with a low concentration of antibodies.
Combination of antibodies was also tested in a curative protocol,
in which 5 LD50 of ricin were administered intranasally and
antibodies at 5 mg/kg intravenously 10 min, 1 h, 5 h, 7.5 h, 10 h
and 24 h after ricin challenge (Figure 6). Antibodies showed a
good efficiency to neutralise ricin toxicity up to 7.5 hours after
intoxication (Fig. 6A), allowing a 90% mice survival. If mAbs were
administered 10 h after intoxication, mice survival falls to 60%,
while 24 h after intoxication, antibodies were only able to delay
mice death. No visible difference was observed in weight loss
between 1 h, 5 h, 7.5 h and 10 h, and weight recovery occurred
rapidly (2 days after intoxication). More surprisingly, weight loss
was more important and recovery more difficult for the mice
injected with antibodies 10 min after ricin challenge (Fig. 6B). In
order to evaluate the ability of each antibody to neutralise in vivo
ricin toxicity, each neutralising antibody was administered
intravenously 1 h after intranasal ricin challenge (5DL50 of ricin
and 5 mg/kg of antibody) (Figure 7). Each of anti-RTB antibodies
(RB34 and RB37) proved to be sufficient to neutralise ricin toxin
(90% and 100% of mice survival respectively, fig. 7A). Anti-RTA
RA36 antibody was less effective to neutralise the toxin with 60%
Figure 1. Immunoblot of ricin identified by several anti-ricin antibodies. 2 mg of ricin was migrated in 15% SDS-PAGE and blotted onto
PVDF membrane. Primary monoclonal antibodies obtained against the A or B chain were incubated for 1 h to bind to ricin. A secondary antibody
HRP-conjugated anti-mouse IgG (diluted 1/2000) was added and proteins were detected after 10 min by chemiluminescence (ECL) using a VersaDoc
imaging system (Bio-Rad). Two lanes are shown for each antibody, corresponding to the migration of ricin and of molecular weight markers (two
lines, 37 and 20 kDa), respectively.
doi:10.1371/journal.pone.0020166.g001
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antibody and the more important for RA36 (Fig. 7B).
Towards the mechanism of action of anti-RTB
neutralising antibodies. As anti-RTA antibody was less
effective in vivo than the anti-RTB ones to inhibit ricin toxicity,
preliminary studies were focused on RB34 and RB37 to try to
understand their mechanism of action. Indeed, according to the
literature, some anti-RTB antibodies could compete with the
galactose binding sites of the B-chain to inhibit ricin entry into
cells. In order to test this hypothesis for our antibodies, a
competition assay using RTB, anti-RTB antibodies and lactose as
competitor was set up (Figure 8). Increasing concentrations of
lactose (from 0, defining B0 i.e 100% of signal, to 100 mM) were
used to compete with anti RTB antibodies for binding to ricin. A
non neutralising anti-RTB antibody, RB18 was used as a control.
RB18 binding to RTB was not modified by lactose. Binding of
RB37 to RTB is inhibited by lactose (IC50=5.2 10
24M),
suggesting that part of RB37 epitope on ricin toxin corresponds
or is close to one of the galactose binding sites. Surprisingly,
binding of RB34 to RTB was favoured by increasing
concentrations of lactose (up to 150% of B0 at 10 mM of
lactose). These effects were specific of the galactose moiety of
lactose, since no difference of RB34 or RB37 binding was
observed when glucose was used as a competitor (data not shown).
Discussion
The use of neutralising antibodies to bind toxins was first
reported in 1894 and is still a treatment of choice, notably for
snake bites and scorpion stings. In terms of biosecurity, there is
now an increased need to develop vaccines and therapeutic
treatments against pathogens and toxins. Ricin is an ubiquitous
toxin devoid of drug treatment. In this context, passive
immunotherapy is thus of great interest and efficient antibodies
should be useful as antidotes both for curative care or for
prevention.
We produced several mAbs against RTA and RTB chains of
ricin. Among the 11 antibodies produced against RTA, four
neutralised ricin toxicity in vitro, while three of the 20 anti-RTB
antibodies counteracted the cytotoxic effect of ricin in vitro.
However, it is worth noting that their potential was not identical.
Anti-RTB mAbs were more effective than anti-RTA mAbs, and
afforded maximum protection (100% cell viability) at a concen-
tration of 3 mg/ml and an IC50 close to 60 ng/ml (for the RB34
one). Anti-RTA mAbs were not as potent, and the best RA33
afforded protection of 70% cell viability at highest concentration
(10 mg/ml) with an IC50 of 1.96 mg/ml (more than 30 times higher
than for RB34). Maddaloni et al. reported opposite results, with
more effective protection using anti-RTA antibodies than anti-
RTB antibodies [17], possibly because of the relative affinities of
the antibodies for the target. The impact of mAb affinity on
protection against toxins has already been studied. Correlation
between antibody affinity and serum neutralisation after vaccina-
tion has been established for tetanus toxin [7], and verified with
the neutralisation of the lethal factor component from Bacillus
Figure 2. Ricin toxicity and antibody neutralising effect in vitro
using a viability assay with Jurkat cells.( A) Evaluation of ricin
toxicity with Jurkat cells. Ricin (0–100 ng/ml) was incubated with
2610
4 cells/ml and cell viability was assessed by means of lumines-
cence assay using the Cell titer Glo luminescence kit (Promega). (B)
Neutralisation assay of ricin using anti-A chain antibodies (RA30:N;
RA35: &; RA36: m; RA32: . and RA33: ¤). (C) Neutralisation assay of
ricin using anti-B chain antibodies (RB18: e; RB27: D; RB34: # and RB37:
%). For Figures (B) and (C), 0.1 ng/ml ricin was pre-incubated with 0–
10 mg/ml antibody and then exposed to 2610
4 cells/ml for 72 h before
assessment of cell viability in the same way as in Figure (A).
doi:10.1371/journal.pone.0020166.g002
Table 2. Calculated concentration of antibodies that allowed
50% cell viability in vitro.
Antibodies IC50 (ng/ml)
RA32 (IgG1)3 1 7 3
RA33 (IgG1)1 9 6 3
RA35 (IgG2b) .10 000
RA36 (IgG1)1 9 8 8
RB27 (IgG2b) 333
RB34 (IgG1) 59
RB37 (IgG1)1 2 7 6
RB34/RB37 41
RB34/RA36 51
RB27/RB37 201
RB37/RA36 112
RB27/RB37/RA36 190
RB34/RB37/RA36 31
doi:10.1371/journal.pone.0020166.t002
Ricin-Neutralising Antibodies
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neutralising antibodies against anthrax toxins [19]. However, in
the present study the different degrees of protection provided by
RB34, RB37 and RA36, based on the in vitro neutralisation assay,
were not related to true differences in affinity for the toxin, as these
three antibodies had similar dissociation constants (KD) ranging
from 0.15 to 0.35 nM. It can thus be hypothesized that the
differences in neutralisation in vitro are more related to the
mechanism of action and epitope specificity of the antibodies than
to their kinetic parameters [20].
Since we produced various antibodies recognising either RTA
or RTB, it was obviously interesting to evaluate and compare
different possible combinations to optimise the neutralising
capability. For RTA, the situation appears rather complex since
RA36 mAb was not compatible with RA30 and RA35, which
nevertheless simultaneously bind different epitopes on ricin. This
result showed that the epitope recognised by RA36 straddles those
of RA30 and RA35. The initial binding compatibility studies
demonstrate that starting from nine anti-RTB mAbs, only RB27
and RB34 are mutually exclusive, as they bind to the same epitope
on RTB and act in the same mechanism. This was confirmed by in
vitro neutralisation assay, since the IC50 obtained with RB34 alone
was greater than the IC50 obtained with the pair RB27/RB34
(data not shown), showing that both antibodies compete for toxin
binding. As expected, all antibodies from one subgroup were
compatible with all antibodies from the other. The in vitro
neutralising assay showed that the best in vitro protection against
ricin was provided by the best anti-RTB antibody (RB34)
combined with the second best compatible anti-RTB antibody
(RB37) and an anti-RTA antibody (RA36), with an IC50 of 31 ng/
ml. Altogether, these results demonstrate as expected that
combining mAbs with different specificities leads to additive or
synergistic effects. However, addition of another further antibody
did not strengthen the neutralisation potency.
Analysis of studies on botulinum neurotoxin [23], anthrax
toxins [16], and more recently SEB toxin [35] shows that the most
effective antidotes include several high-affinity and non-cross-
reacting mAbs (or Fabs). This was confirmed in the present study,
since the results obtained in the mouse protection assay clearly
demonstrate that a combination of three antibodies (RB34, RB37
and RA36) provides very good protection against a 5 LD50 ricin
challenge. Even an antibody/ricin molar ratio of five, i.e. less than
two molecules of each of the three antibodies for one molecule of
ricin, allows a survival rate of 60%; the rate is 100% with a ratio of
10 (i.e. 4.7 mg of antibodies). The 80% survival observed at a ratio
of 20 was not statistically different from the 100% observed at a
ratio of 10. It is worth noting that at a ratio of 2, despite 100%
mortality, the delay before death was statistically increased. We
also evaluated this combination of antibodies in a curative
protocol. Mixture of antibodies proved to be efficient to protect
Figure 3. Combination neutralising effect of antibodies against
ricin in vitro. (A) Combination of pairs of antibodies, with RB34 as
control (RB34: #; RB34/RB37: m; RB34/RA36: ¤; RB37/RA36: .; RB27/
RB37: &). (B) Combination of three or four antibodies, with RB34 as
control (RB34: #; RB27/RB37/RA36:N; RB34/RB37/RA36: m; RB34/RB37/
RA36/RA32: +; RB34/RB37/RA36/RA33: &; RB34/RB37/RA36/RA35: ¤).
Antibodies were premixed in equimolar ratio at several concentrations
(0–10 mg/ml) and incubated with ricin (0.1 ng/ml) before exposure to
Jurkat cells. Cell viability was assessed by means of luminescence assay
using a Cell titer Glo luminescence kit (Promega).
doi:10.1371/journal.pone.0020166.g003
Table 3. Affinity constants of RB34, RB37 and RA36 for ricin.
mAbs koff (s
21) 610
25 kon (M
21.s
21) 610
5 KD (M) 610
210
RB34 3.6660.27 2.4860.34 1.5060.19
RB37 7.3460.12 3.3360.39 2.2460.24
RA36 5.5360.44 1.5860.16 3.5160.46
*KD was calculated from kon and koff with n=3 for each antibody.
doi:10.1371/journal.pone.0020166.t003
Figure 4. Pharmacokinetic study of RB34, RB37 and RA36 in
mice. Purified antibody (50 mg) was injected intraperitoneally into
Swiss mice (n=4). Mice were sacrificed at different times to calculate
plasma concentration of mAbs: RB34 (&); RB37 (m) and RA36 (N), using
an immunoassay.
doi:10.1371/journal.pone.0020166.g004
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to previous published data for anti RTA antibodies [28]. We then
analysed the contribution of each antibody to neutralise ricin in
vivo and the anti-RTB neutralising antibodies appeared more
powerful than the anti-RTA antibody. Moreover, use of RB34 and
RB37 alone at 5 mg/kg allowed an almost complete protection
against ricin intoxication.
According to the literature, some anti-RTB antibodies might
block toxin binding to the cell by interfering with galactose-
binding sites [6,18,20]. We were thus wondering whether our anti-
RTB antibodies could interfere with galactose binding on ricin
chain B. Binding of RB34 and RB37 to ricin are influenced by
galactose in opposite ways. RB37 binding to ricin is inhibited by
galactose and this mAb would thus act by blocking ricin binding to
the cell surface through steric hindrance. Conversely, RB34
binding to ricin is enhanced in presence of galactose further
suggesting that this antibody would not prevent ricin binding to its
target and might act after ricin binding to the cell. The exact
epitope recognised by RB34 and the way of inhibiting ricin toxin
are currently under investigation.
Mechanism of inhibition of our anti-RTA neutralising antibody
is still unknown. It has been described that RTA is subdivided in
three folding subdomains, domains 1 and 2 being targets of
protective antibodies [24]. In the subdomain 2, peptide 163–174 is
sufficient to elicit immunity to ricin [21] and antibody against this
peptide partially blocks enzymatic activity. Whether our RA36
antibody would recognise this part of RTA and how it could exert
its partial neutralising effect by blocking the catalytic site, or slow
down the trafficking process of the toxin by interfering with
vesicular retrograde transport or translocation of the RTA across
the endoplasmic reticulum [18] remains to be determined.
From the pharmacokinetic studies, the calculated half-lives of the
antibodies were close to 15 days, with a peak plasma concentration
5 to 20 h after intraperitoneal injection. These results will be useful
for further experiments on prophylaxis in mice. Antibodies could be
injected the day beforericin challenge for optimal distribution at the
Figure 5. In vivo neutralising activity of anti-ricin antibodies
combination pre-incubated with ricin (A) Survival curve. CD1
mice were intranasally challenged with 5 LD50 of ricin alone (D) or pre-
incubated with antibodies: several doses of RA36, RB34 and RB37
mixture (Abs) were assessed to obtain antibody/ricin molar ratios of 2
(&), 5 (N), 10 (m) and 20 (¤), compared with a nonspecific antibody
(ns Ab) in the same concentration (R=2 (+), R=5 (X), R=10 (#), R=20
(%)). 50 ml of ricin-antibody complex was administered per mouse and
mortality was monitored for 21 days. (B) Weight change. In the same
experiment, mice were weighed at 0, 2, 7, 14 and 21 days. The
percentage of the D0 weight (100%) was calculated, with female CD1
mice as control (.). Mice injected with ricin alone (D) or with mixtures
of specific antibodies at R=2 (&); R=5 (N); R=10 (m) and R=20 (¤).
The data are representative of two independent experiments.
doi:10.1371/journal.pone.0020166.g005
Figure 6. In vivo neutralising activity of anti-ricin antibodies
combination administered after ricin challenge. (A) Survival
curve. CD1 mice were intranasally challenged with 5 LD50 of ricin alone
(D) or ricin followed by intravenous injection of 5 mg/kg of antibodies
10 min (&), 1 h (N), 5 h (¤), 7.5 h (m), 10 h (#) and 24 h (%) after
challenge. (B) Weight change. In the same experiment, mice were
weighed at 0, 2, 7, 14 and 21 days, taking the weight at day zero as
reference (100%), for female CD1 mice as a control (.), mice injected
with ricin (D), or ricin followed by intravenous injection of 5 mg/kg of
antibodies 10 min (&), 1 h (N), 5 h (¤), 7.5 h (m), 10 h (#) and 24 h
(%) after challenge. The data are representative of two independent
experiments.
doi:10.1371/journal.pone.0020166.g006
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potential prophylaxis in human subjects, intravenous injection for
immediate availability and protection against the toxin will be
considered. These different experiments are currently ongoing with
the aim of establishing the potential of these mAbs for immuno-
therapeutic treatment of ricin poisoning.
Materials and Methods
Animal experimentation
All experiments were performed in accordance with French and
European Community guidelines for laboratory animal handling.
The protocols of the in vivo neutralisation assays of ricin were
approved by the French Health Products Safety Agency(AFSSAPS;
protocol no. 2010-CBR-003). All surgery was performed under
anesthesia (xylasine/ketamine), and all efforts were made to
minimize suffering.
Swiss (CD1) mice (IOPS) used for pharmacokinetic experiments
were from Elevage Janvier (Nantes, France) and CD1 (IOPS) mice
used for mouse protection assays were from Charles River
laboratories (Lyon, France).
Reagents
Biotin, streptavidin, whole ricin toxin, RTA and RTB were
from Sigma. Ricin toxin used for in vivo assay was a gift from Dr
Beaumelle (CNRS laboratory). Immunoassays were performed
with 96-well microtiter plates (Maxisorp, Nunc [Roskilde, Den-
mark]) and all reagents were diluted in enzyme immunoassay
(EIA) buffer (0.1 M phosphate buffer pH 7.4 containing 0.15 M
NaCl, 0.1% bovine serum albumin and 0.01% sodium azide).
Plates coated with proteins were saturated in EIA buffer (18 h at
4uC) and washed with washing buffer (0.01 M potassium
phosphate pH 7.4 containing 0.05% Tween 20).
Production of monoclonal antibodies against ricin chains
A and B
Balb/C mice were immunised once a month for 4 months with
either 12.5 mg of RTB or 5 mg of RTA in complete Freund’s
adjuvant (foot pad injection). Mice were bled two weeks after each
immunisation to evaluate and monitor the polyclonal anti-RTA or
anti-RTB response in the sera using a specific EIA (see below).
The mouse presenting the highest titer was selected for prepa-
ration of monoclonal antibodies. Three days before fusion of the
spleen cells with the myeloma, the mouse was given a final booster
injection (10 mg antigen, i.v. injection). Hybridomas were
produced by fusing spleen cells from immunised Balb/c mice
with NS1 myeloma cells according to the procedure previously
described [13]. Anti-ricin antibodies secreted in culture superna-
tants were screened using an enzyme immunoassay (EIA, see
below). Selected hybridomas were subsequently cloned by limiting
dilution and monoclonal antibodies produced in ascites fluids in
mice. MAbs were further purified using caprylic acid precipitation
[27]. After screening for neutralising properties, the interesting
mAbs were purified by affinity chromatography using protein A
(ProsepA, Millipore) [11]. Their purity was assessed by polyacryl-
Figure 7. In vivo evaluation of each neutralising anti-ricin
antibody administered after ricin challenge. (A) Survival curve.
CD1 mice were intranasally challenged with 5 LD50 of ricin alone (D)o r
ricin followed by intravenous injection of 5 mg/kg of RB34 antibody
(&), RB37 antibody (N), or RA36 antibody (%) 1 h after ricin challenge.
(B) Weight change. In the same experiment, mice were weighed at 0, 2,
7, 14 and 21 days, taking the weight at day zero as reference (100%), for
female CD1 mice as a control (.), mice injected with ricin (D), or ricin
followed by intravenous injection of 5 mg/kg of mouse weight of RB34
antibody (&), RB37 antibody (N), or RA36 antibody (%) 1 hour after
ricin challenge.
doi:10.1371/journal.pone.0020166.g007
Figure 8. Competition of lactose with antibodies binding to
ricin. Neutralising anti-RTB antibodies RB34 (%) and RB37 (N) and a
non neutralising antibody (RB18) used as control (m) were incubated at
75 ng/ml with increasing concentrations of lactose (from 0 to 10 mM)
and biotin-labeled RTB (25 ng/ml) in a microtiter plate coated with a
polyclonal anti-mouse antibody. Antibodies binding to ricin were
further revealed using streptavidin-AChE and Ellman’s reagent.
Absorbance was measured at 414 nm. B and B0 correspond to the
absorbance obtained with or without competitor, respectively, allowing
to calculate B/B0 (expressed as %) for each point.
doi:10.1371/journal.pone.0020166.g008
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reducing conditions.
Enzyme immunoassay
Labeling of proteins with biotin. Proteins or mAbs were
labeled with biotin and used as conjugates in enzyme im-
munoassays. 0.67 nmol of antibody or 1.6 nmol of RTA or RTB
dissolved in 400 ml of 0.1 M borate buffer pH 9 was incubated with
13.3 nmoles and 32.2 nmoles of biotin-N-hydroxysuccinimide ester
(Sigma) respectively dissolved in anhydrous DMF. After 30 min at
room temperature (RT), 100 ml of 1 M Tris-HCl pH 8 was added
for 1 h at RT. Finally, 500 ml of EIA buffer was added and this
preparation was stored frozen at 220uC until use.
Evaluation of polyclonal response and screening of mAbs
in hybridoma supernatants. Anti-ricin antibodies were
detected in sera of immunised mice or hybridoma culture
supernatants using EIA. Briefly, 50 ml of serial dilutions of
mouse serum in EIA buffer or of each culture supernatant from
96-well culture plates was transferred into microtiter plates coated
with goat anti-mouse IgG+IgM antibodies (Jackson Immuno-
research laboratories), before adding 50 ml of biotinylated-RTA or
biotinylated-RTB (100 ng/ml). After 18 h reaction at 4uC, plates
were washed and 100 ml of AChE-labeled streptavidin conjugate
(2 Ellman units [EU]/ml) was added to each well. After 2 h
incubation at RT followed by three washing cycles, 200 mlo f
Ellman’s reagent [9] was added and the absorbance was measured
at 414 nm after 1 h.
Determination of the antibody concentration in mouse
plasma. Diluted plasma and purified antibodies used as
standard (concentration ranging from 0 to 13.3 ng/ml), were
incubated for 18 h at 4uC in 96-microtiter plates coated with
whole ricin (100 ng/well). After three washing cycles, 100 mlo f
3 EU/ml AChE-labeled goat anti-mouse IgG (conjugate antibody)
was added for 2-h reaction. After three washing cycles, 200 mlo f
Ellman’s reagent was added to each well and absorbance was
measured at 414 nm after 30 min reaction at RT.
Determination of binding complementarity for each pair
of mAbs. A combinatorial analysis of mAbs was performed to
evaluate their simultaneous binding to whole ricin. A two-site
immunometric test was carried out using one antibody im-
mobilized on solid phase for capture and the other as a biotin-
labeled conjugate. To determine the ‘‘binding complementarity’’,
experiments were performed by adding 100 ml of ricin (100 ng/ml)
and 100 ml of biotin-labeled mAb (100 ng/ml) to the microtiter
plate previously coatedwith oneof the mAbs (1 mg/well). After 18 h
reaction at 4uC, plates were washed before adding 200 ml/well of
AChE-labeled streptavidin conjugate (2 EU/ml) for 1 h reaction at
RT. Absorbance at 414 nm was read after 1 h reaction at RT with
200 ml of Ellman’s reagent.
Competition assay of lactose with anti-RTB antibodies to
ricin binding. 50 ml of each anti-RTB mAb (75 ng/ml) were
added together with 50 ml of biotin-labeled RTB (25 ng/ml) and
50 ml of different concentrations of lactose as competitor (from 0 to
10 mM) in 96 microtiter plates coated with goat anti-mouse IgG. A
negative control using glucose as competitor was used.After 18 h
reaction at 4uC, plates were washed before adding 200 ml/well of
AChE-labeled streptavidin conjugate (2 EU/ml) for 1 h reaction at
RT. Absorbance at 414 nm was read after 1 h reaction at RT with
200 ml of Ellman’s reagent.. %B/B0 corresponds to the ratio of
sample absorbance (B) as compared to the absorbance measured
without competitor (B0, corresponding to 100% binding).
Western blot analysis. mAbs were tested for their ability to
recognise ricin in denaturing and reducing conditions by western
blot analysis. Whole ricin was solubilised in Laemmli buffer in
reducing conditions (0.25 M Tris-HCl pH 6.8, 4% SDS, 40%
glycerol, 0.1% bromophenol blue and 10% b-mercaptoethanol
[5]) for 5 min at 95uC. After migration of 2 mg/well of ricin in
SDS-PAGE (15% resolving), proteins were blotted onto a PVDF
membrane (Amersham Biosciences). Membranes were saturated
with PBS containing 0.1% Tween 20, 5% bovine serum albumin
and further incubated with the different anti-RTA and RTB mAbs
(2 mg/ml) for 1 h at RT. After several washings in PBS containing
0.1% Tween 20, membranes were reacted with a secondary HRP-
conjugated anti-mouse IgG (1/2000 [Pierce]) for 20 min at RT.
Membranes were washed and proteins bands were detected via
chemiluminescence (ECL, Amersham Biosciences) using a
VersaDoc imaging system (Bio-Rad).
In vitro neutralising assays of ricin. The in vitro
neutralisation of ricin was evaluated using a Jurkat cell viability
assay. Jurkat cells (from ATCC) were grown at 37uC with 5%
CO2, in RPMI 1640 medium supplemented with 10% fetal calf
serum, 1% glutamine, 1% sodium pyruvate, 1% penicillin/
streptomycin. A standard curve of ricin toxicity was plotted for a
ricin concentration range from 0 to 100 ng/ml, using
quadruplicate measurements. Neutralising effects of antibodies
were tested with a constant ricin concentration of 0.1 ng/ml (i.e.
1.56 pM, the lowest concentration that kills more than 95% of
cells). Purified antibodies (concentration ranging from 0 to 10 mg/
ml, i.e. 67 nM) were mixed with the toxin in a 50 ml volume and
incubated for 30 min at 37uC in 96-well plates. Cells were
resuspended at a density of 2610
4 cells/ml and 50 ml (1000 cells)
was added to the mixture. After 3 days of incubation at 37uC, a
luminescence assay with the Cell titer Glo luminescence kit
(Promega) was used to measure cell viability. 100% viability was
assessed with samples without ricin (cells only), allowing
calculation of the percentage viability for each sample.
Synergistic effects of neutralising mAbs against ricin were
evaluated for combinations of two, three or four mAbs in equal
proportions (0 to 67 nM in total), applied to cells in the same
conditions as described above.
Determination of mAb affinity by surface plasmon
resonance. The affinities of neutralising mAbs were deter-
mined by surface plasmon resonance (SPR) in a BIAcore2000
instrument (Biacore, Sweden). All analyses were performed at 25uC
on a CM5 sensor chip in the running buffer HBS-EP (10 mM
Hepes, 150 mM NaCl, 3 mM EDTA and 0,005% surfactant P20,
pH 7.4).Ananti-mouseIgGwasconjugatedtothe sensorchipusing
the mouse antibody capture kit (GE Healthcare) according to the
manufacturer’s instructions. Experiments were performed assuming
the existence of a high-affinity antigen/antibody complex [8]. For
all neutralising antibodies, kinetic analyses were performed by
indirect binding to this CM5 immobilised anti-mouse IgG. The
antibody of interest (2 mg/ml) was injected at 5 ml/min for 3 min.
After a 10-min stabilisation, whole ricin (concentrations ranging
from 0.5 nM to 30 nM) was injected for 3 min at a constant flow
rate of 40 ml/min to obtain a maximum signal of 150 resonance
units (RU). Dissociation was monitored over a period of 45 min
before the chip was regenerated with 10 mM glycine pH 1.7 for
30 s at a flow rate of 50 ml/min. The equilibrium dissociation
constant (KD) was calculated using the ratio between the
dissociation rate constant (koff) and the association rate constant
(kon), as previously described [14], using a Langmuir 1:1 fit
(BIAevaluation SoftwareH, v3.2).
Pharmacokinetic analyses of mAbs in mouse. Male CD1
mice 6–8 weeks old (body weight 28 to 32 g) were used for the
pharmacokinetic study. 50 mg of 0.22 mm filtered antibodies
diluted in PBS buffer was intraperitoneally administered to mice
(n=4). Mice were anaesthetized intraperitoneally with 200 mlo fa
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blood sampling. Blood was collected 1, 7, 24, 48, 96, 360, 576 and
1032 h after mAb injection and centrifuged for 30 min at 3500 g
at 4uC. Plasma was recovered and stored at 220uC until use.
Plasma concentration of antibodies was measured by EIA.
Pharmacokinetic parameters were determined using the mean
antibody concentrations in mice (n=4) per time point. For
calculation of in vivo blood clearance, data values were fitted using
WinNonlin software (Pharsight).
Mouse protection assay of ricin using the combination of
three monoclonal antibodies. The ability of a combination of
antibodies to protect mice against ricin poisoning was studied in vivo
using female CD1 mice weighing 22–25 g. Ricin purified from
castor beans as previously described [22] was a generous gift of Dr.
Beaumelle (CNRS). Ricin LD50 (lethal dose that kills 50% of mice)
wasevaluatedat1.5 mg/kgusingtwoindependentassaysinamouse
model with intranasal challenge of ricin (data not shown). Mouse
protection was evaluated with a constant ricin concentration of
7.5 mg/kg (5 LD50) and several antibody concentrations (0.9, 2.3,
4.7 and 9.4 mg/mouse corresponding to a molar ratio [mAbs vs
ricin] of 2, 5, 10 and 20, respectively N=10 per experimental
group).Antibodiesweremixedinequimolarratioasforinvitroassay.
Ricin and antibodies were pre-incubated in 50 mM phosphate
buffer pH 7.4, 150 mM NaCl and 1 mg/ml gelatin for 1 h at RT
before intranasal administration of 50 ml/mouse (n=10). A
negative test was performed with nonspecific antibodies directed
against another toxin (anti-botulinum neurotoxin A antibody). Mice
wereweighed on days0, 2, 7, 14,and 21 and observed daily until 21
days to plot a survival curve.
Therapeutic protection assay against ricin using the
combination of three monoclonal antibodies. 5 LD50 of
ricin was administered intranasally and combination of RA36,
RB34 and RB37 antibodies (500 ml, 5 mg/kg, N=10 mice per
group) was injected intravenously at 10 min, 1 h, 5 h, 7.5 h, 10 h
and 24 h after ricin administration. Mice were weighed on days 0,
2, 7, 14, and 21 and observed daily until 21 days to plot a survival
curve.
Evaluation of each neutralising antibody in a mouse
protection assay. 5 LD50 of ricin was administered
intranasally and each of RA36, RB34 and RB37 antibodies
(500 ml, 5 mg/kg, N=10 mice per group) was injected
intravenously 1 h after ricin administration. Mice were weighed
on days 0, 2, 7, 14, and 21 and observed daily until 21 days to plot
a survival curve.
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